Brokerages Set Ardent Health Partners, LLC (NYSE:ARDT) Price Target at $21.55

Shares of Ardent Health Partners, LLC (NYSE:ARDT) have received a consensus rating of “Buy” from the twelve research firms that are covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $21.55.

A number of research firms recently issued reports on ARDT. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $20.00 price target on shares of Ardent Health Partners in a research note on Tuesday, December 17th. Leerink Partners lifted their target price on shares of Ardent Health Partners from $23.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Royal Bank of Canada reissued an “outperform” rating and set a $23.00 target price on shares of Ardent Health Partners in a research note on Thursday, November 14th. Bank of America lowered shares of Ardent Health Partners from a “buy” rating to a “neutral” rating and decreased their price target for the company from $22.00 to $19.00 in a research note on Wednesday, November 6th. Finally, Truist Financial cut their price objective on Ardent Health Partners from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Monday, January 6th.

Ardent Health Partners Stock Down 0.8 %

NYSE:ARDT opened at $15.09 on Monday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.78 and a current ratio of 1.91. Ardent Health Partners has a 52 week low of $13.63 and a 52 week high of $20.72. The stock’s 50-day moving average price is $15.80 and its 200-day moving average price is $17.08.

Ardent Health Partners (NYSE:ARDT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.19 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.10). The business had revenue of $1.45 billion during the quarter, compared to the consensus estimate of $1.46 billion. Sell-side analysts predict that Ardent Health Partners will post 1.22 EPS for the current year.

Hedge Funds Weigh In On Ardent Health Partners

Institutional investors have recently added to or reduced their stakes in the stock. State Street Corp acquired a new position in shares of Ardent Health Partners during the 3rd quarter valued at about $1,977,000. Jane Street Group LLC purchased a new position in Ardent Health Partners during the third quarter worth about $567,000. Allspring Global Investments Holdings LLC acquired a new position in Ardent Health Partners in the 3rd quarter valued at about $13,119,000. Goldentree Asset Management LP purchased a new stake in shares of Ardent Health Partners in the 3rd quarter valued at approximately $22,897,000. Finally, Barclays PLC acquired a new stake in shares of Ardent Health Partners during the 3rd quarter worth approximately $385,000.

About Ardent Health Partners

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.